2-[(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenylamino]-ethanol | 26203-39-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenylamino]-ethanol
• CAS: 26203-39-4
• 化学式: C₂₂H₃₅NO
• 分子量: 329.526
• InChiKey: XZSDEYZQEXYTHR-IRHGQBOFSA-N

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS POUR LE TRAITEMENT D'UNE MALADIE
  申请人：ACUCELA INC

  公开号：WO2013109991A1

  公开（公告）日：2013-07-25

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted heterocyclic amine derivative compound and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明一般涉及治疗神经退行性疾病和紊乱的组合物和方法，特别是眼科疾病和紊乱。本文提供了替代杂环胺衍生物化合物和包含这些化合物的药物组合物。所述组合物对治疗和预防眼科疾病和紊乱，包括年龄相关性黄斑变性（AMD）和Stargardt病具有用处。
• [EN] ALKOXY COMPOUNDS FOR DISEASE TREATMENT<br/>[FR] COMPOSÉS D'ALCOXY POUR LE TRAITEMENT DE MALADIES
  申请人：ACUCELA INC

  公开号：WO2009045479A1

  公开（公告）日：2009-04-09

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明通常涉及治疗神经退行性疾病和紊乱的组合物和方法，特别是治疗眼科疾病和紊乱的组合物和方法。本文提供了烷氧基衍生物化合物和包含这些化合物的药物组合物。所述组合物对治疗和预防眼科疾病和紊乱，包括年龄相关性黄斑变性（AMD）和斯塔加特病（Stargardt's Disease）具有用处。
• [EN] METHODS OF USE FOR OPSIN BINDING LIGANDS<br/>[FR] PROCÉDÉS D'UTILISATION DE LIGANDS DE LIAISON DE L'OPSINE
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2010074746A1

  公开（公告）日：2010-07-01

  Methods of use of compounds of the Formula I1 II, III, IV and/or V are disclosed for treating ophthalmic conditions related to the production of toxic visual cycle products that accumulate in the eye, and are associated with reactions of the visual cycle during medical procedures that expose the eye to light, most commonly the various forms of ophthalmic surgery and stabilize the proper folding of mutant opsins. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said treatments.

  公开了利用公式I1 II、III、IV和/或V的化合物治疗与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的方法，这些产物与暴露于光线的医疗程序期间的视觉循环反应有关，最常见的是各种形式的眼科手术，并稳定突变视蛋白的正确折叠。还描述了在这些方法中有用的化合物和组合物，无论是单独使用还是与其他治疗剂结合使用，以及筛选用于上述治疗的新药物的方法。
• Retinyl derivatives for treating ophtalmic conditions
  申请人：Sirion Therapeutics, Inc.

  公开号：EP2025336A1

  公开（公告）日：2009-02-18

  Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.

  导致可逆性夜盲症的化合物可用于治疗与视觉周期过程中积累的废物过度产生有关的眼科疾病。我们描述了使用此类化合物及其衍生物治疗黄斑变性和营养不良等眼科疾病或缓解与此类眼科疾病相关的症状的方法和组合物。此类化合物及其衍生物可用作单药治疗，也可与其他药物或疗法联合使用。
• METHODS AND REAGENTS FOR THE IDENTIFICATION AND REGULATION OF SENESCENCE-RELATED GENES
  申请人：GERON CORPORATION

  公开号：EP0789780A1

  公开（公告）日：1997-08-20